本研究首次报道了荧光激活细胞分选（FACS）和单细胞电感耦合等离子体质谱（SC-ICP-MS）的联合应用。本研究利用这一方法评估了超小型氧化铁纳米颗粒（FeNPs）负载顺铂前药（FeNPs-Pt(IV)）和顺铂在细胞内摄取方面的差异，以及与细胞存活率的关系。为了达到这个目的，我们采用FACS技术将A2780卵巢癌细胞分为存活、凋亡和坏死三个亚群，分别接触纳米载药和顺铂。然后，我们利用量化的SC-ICP-MS技术对不同的分选细胞群体进行个体分析，以确定细胞内顺铂的含量。当使用FeNPs-Pt(IV)纳米前药时，凋亡细胞群体中的Pt细胞内含量最高（约2.1 fg Pt/细胞），且其在细胞间分布较为狭窄（占总细胞数的75%）。而在经过顺铂处理的细胞中，存活细胞群体中的Pt含量最高（约1.6 fg Pt/细胞）。这种前所未有的联合方法提供了更准确细胞内药物含量和与游离药物及纳米载药相关的细胞死亡机制的全貌，并为分选细胞群体中的许多可能的单细胞实验打开了新的研究方向。

The combined use of fluorescence-activated cell sorting (FACS) and single-cell inductively coupled plasma mass spectrometry (SC-ICP-MS) is reported, for the first time, in this work. It is applied to evaluate the differences between the cellular uptake of ultrasmall iron oxide nanoparticles (FeNPs) loaded with cisplatin(IV) prodrug (FeNPs-Pt(IV)) and cisplatin regarding cell viability. For this aim, FACS is applied to separate viable, apoptotic, and necrotic A2780 ovarian cancer cells after exposing them to the nanotransported prodrug and cisplatin, respectively. The different sorted cell populations are individually analyzed using quantitative SC-ICP-MS to address the intracellular amount of Pt. The highest Pt intracellular content occurs in the apoptotic cell population (about 2.1 fg Pt/cell) with a narrow intercellular distribution when using FeNPs-Pt(IV) nanoprodrug and containing the largest number of cells (75% of the total). In the case of the cisplatin-treated cells, the highest Pt content (about 1.6 fg Pt/cell) could be determined in the viable sorted cell population. The combined methodology, never explored before, permits a more accurate picture of the effect of the intracellular drug content together with the cell death mechanisms associated with the free drug and the nanotransported prodrug, respectively, and opens the door to many possible single-cell experiments in sorted cell populations.